The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention

CONCLUSIONS: The CHADS-P2A2RC risk score is valuable in discriminating high-ischemic-risk patients. Even in such patients with a high risk of ischemic events, P2Y12 inhibitor monotherapy was associated with a lower incidence of bleeding without increased risk of ischemic events compared with prolonged DAPT.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02079194.PMID:38654565 | DOI:10.4070/kcj.2023.0268
Source: Korean Circulation Journal - Category: Cardiology Authors: Source Type: research